# Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

> **NCT07199855** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Zhejiang University** · enrollment: 24 (estimated)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukemia, Adult

## Interventions

- **DRUG:** blinatumomab combined with venetoclax as maintenance therapy

## Key facts

- **NCT ID:** NCT07199855
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199855, "Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07199855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*